PHPaul A. Harris

Paul A. Harris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul A. Harris has a total of 738 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A comparison of Fast Healthcare Interoperability Resources and Observational Medical Mutcomes Partnership electronic health record data within the All of Us Research Program

    by Jason Patterson, Elise Minto, Maura Beaton, Adit Anand, Mark Velez, Paul Harris, George Hripcsak, Karthik Natarajan

    Objective: This study compares the contents of two data standards; the Observational Medical Outcomes Partnership (OMOP) and Fast Healthcare Interoperability Resources (FHIR), highlighting their strength and weaknesses and serve as an initial step toward understanding how each standard supports secondary data analysis. Materials and Methods: Participant electronic health record data in both OMOP and FHIR formats from the All of Us Research Program (AoURP) were compared, including codeable event volume, healthcare encounters, and person timelines. A phenotype-based assessment was also conducted using Type-II Diabetes Mellitus (T2DM). Results: Among 29 512 participants identified with overlapping FHIR and OMOP data, Median codeable event counts were comparable between FHIR and OMOP within the Measurement (OMOP = 846; FHIR = 832), Drug (OMOP = 92; FHIR = 90), and Observation (OMOP = 65; FHIR = 100) domains, but were higher in OMOP within the Condition (OMOP = 258; FHIR = 11) and Procedure (OMOP = 72; FHIR = 4) domains. Within the T2DM cohort, OMOP contained more data, except for medications. Very few participants had encounters in FHIR (1.5%) relative to OMOP (97.0%). On average, only 15.9% of visit dates overlapped in both standards, with most visit dates occurring only in OMOP (65.3%) or only FHIR (18.4%). Discussion: Data in OMOP showed a higher volume of observation and procedure codeable events, reported encounters, and T2DM symptoms, complications, and comorbidities. FHIR data was able to capture data across multiple providers and health systems. Conclusion: Based on AoURP data, both standards were shown to support healthcare data capture, although OMOP shows greater utility for research purposes as its extract, transform, and load process enables more flexible data capture relative to extracting data from FHIR payloads. FHIR, however, captures patient-level data from beyond the health system and can thus be used to supplement OMOP.


  • Open Access

    Social media toolkit for recruiting clinical research participants: A new resource from the Recruitment Innovation Center

    by Sarah K. Cook, Stephanie A. Mayers, Matt Schorr, Caitlin Rantala, Sophia Gomez, Meghan Vance, Danielle Pardue, Terri L. Edwards, Mary Stroud, Paul A. Harris, et al.

    Social media offers research teams new opportunities for outreach and study recruitment; however, research teams often need guidance and tools on how to use social media to effectively recruit for their clinical trials. To address this gap, the Recruitment Innovation Center (RIC) developed a new, comprehensive toolkit informed by community feedback and extensive RIC experience. The toolkit contains guidance and considerations for using social media to recruit clinical trial participants, including best practices, platform-specific strategies, and customizable templates. This paper details the creation and contents of this new, free resource.

  • Open Access

    Generative artificial intelligence implementation in REDCap

    by Cathy Shyr, Robert Taylor, Vaishali Jagtap, Alex C Cheng, Paul A Harris

    Objective: To describe the Research Electronic Data Capture (REDCap) Consortium’s initial implementation of generative artificial intelligence (AI) within the REDCap platform using a minimum viable product (MVP) strategy. Materials and methods: Guided by principles of security, optional adoption, and “human-in-the-loop” oversight, we developed and implemented three AI-assisted features: a writing helper, qualitative data summarization, and language translation. Features were disseminated as part of REDCap release 15.0. Results: During the first seven months post-release (January-August 2025), 18 institutions worldwide activated the REDCap generative AI module, with eight reporting sustained use across 1171 projects. At Vanderbilt University Medical Center, 958 projects used at least one feature, generating over 5700 generative AI API calls. Discussion: Early uptake demonstrates feasibility and researcher interest, though adoption depends on local AI tenant infrastructure and governance. Conclusion: The MVP provides generalizable lessons for securely and responsibly deploying generative AI within research electronic data capture systems.


  • Open Access

    Multi-scale data improves performance of machine learning model for long COVID identification

    by Christopher Guardo, Zhang Xinmeng, Srushti Gangireddy, Yan Chao, V. Eric Kerchberger, Alyson L. Dickson, Emily R. Pfaff, Hiral Master, Xin Yi, Melissa Basford, et al.

    Background Long COVID affects a substantial proportion of the over 778 million individuals infected with SARS-CoV-2, yet predictive models remain limited in scope. While existing efforts, such as the National COVID Cohort Collaborative (N3C), have leveraged electronic health record (EHR) data for risk prediction and identification, accumulating evidence points to additional contributions from social, behavioral, and genetic factors. Methods Using a diverse cohort of SARS-CoV-2-infected individuals (n > 17,200) from the NIH All of Us Research Program, we investigated whether integrating EHR data with survey-based and genomic information improves model performance. Results Our multi-scale approach outperforms EHR-only model’s area under the receiver operating curve 0.736 (95% CI: 0.730, 0.741), achieving an area of 0.748 (0.741,0.755). Among the top predictors, active-duty service status, and self-reported fatigue are the most informative survey features. Conclusions These findings highlight the importance of incorporating multi-scale data to improve risk stratification and inform personalized interventions for long COVID. However the relative increase in accuracy is modest, and the cost of collecting genetic and survey data should be considered before implementation.


  • Open Access

    Use of advance letters to enhance participant retention in a clinical trial

    by Sarah K Cook, Meghan Mayhew, Sarah J. Nelson, P. Suzanne Aycock, Consuelo H. Wilkins, Paul A. Harris, Lynn DeBar

    In randomized clinical trials, participant retention is critical to ensure the validity and unbiased interpretation of study results. Within a multisite trial of individuals with high impact chronic pain, we explored whether a letter mailed in advance of follow-up study assessments at 3-, 6-, and 12-months from randomization improved participant retention. 4063 advance letters were mailed to 2037 participants at least once throughout their study participation. Increases in participant retention and follow-up assessment rates were observed across all study groups, sites, and timepoints. Mailing a letter in advance of follow-up study assessments in this randomized clinical trial improved participant retention.


  • Open Access

    Collaborative compliance: A consortium-based framework for achieving 21 CFR part 11 readiness in REDCap across CTSA institutions

    by Theresa A. Baker, Teresa Bosler, April D. Green, Jason Lones, Katie E. Keenoy, Bridget M. Adams, Bas de Veer, Brian J. Bush, Stephanie R. Oppenheimer, Sheree A. Hemphill, et al.

    Academic research institutions using REDCap often face challenges aligning with U.S. FDA requirements for electronic records and signatures under 21 CFR Part 11 (Part 11). A National Center for Advancing Translational Sciences(NCATS) working group developed an implementation guide for Part 11 compliance in REDCap. Within six months after release, 259 individuals representing 164 institutions accessed the guide. Individuals who downloaded the guide reported reduced vendor reliance, improved documentation, and establishment Part 11-ready REDCap instances. This working group demonstrated how collaboration between technical and regulatory experts at many peer institutions is effective in improving regulatory compliance across the research enterprise.

  • Open Access

    Investigating the Use of the Fast Health Care Interoperability Resources (FHIR) Standard to Support Data Activities Across the PCORnet® Infrastructure: Lessons Learned From the FHIR Pilots of the Coordinating Center for PCORnet®

    by Keith Marsolo, Darcy Louzao, Kim Hart, Peter Shrader, Jeffrey Hawley, Francesco Delacqua, Ellis Thomas, Joseph Wick, Alanna M. Chamberlain, William S. Jones, et al.

    Background: Institutions that participate in PCORnet ® transform their local electronic health record (EHR) data into the PCORnet ® Common Data Model (CDM), which is then used to generate data extracts for PCORnet ® Studies. PCORnet ® Studies can also include institutions that do not participate in PCORnet, and for these organizations, the cost of instantiating a PCORnet ® CDM can be prohibitive. Fast Health care Interoperability Resources (FHIR) provides an alternative method of obtaining EHR data. Objective: To determine whether data obtained through FHIR might be a viable study solution for those sites that do not participate in PCORnet. ® This mixed-methods project had 2 objectives: (1) survey sites participating in PCORnet on the availability of FHIR (FHIR survey); (2) compare the coverage of a FHIR-based data extract using REDCap with one from the PCORnet ® CDM across 3 sites (FHIR extract). Methods: (1) FHIR survey: A series of questions were asked about the use of FHIR in a production capacity. (2) FHIR extract: REDCap FHIR and PCORnet ® CDM extracts were created based on study variables from 2 prior PCORnet ® Studies. Data were extracted for 40 patients and concordance measures were computed between the 2 sources. Results: (1) FHIR survey: Of responding organizations, 73% (n=49) reported that FHIR was deployed in a production capacity. (2) FHIR extract: Results were highly variable. Cohen kappa ranged from 0.01 to 0.76 for certain diagnoses, 0.24 to 0.84 for laboratory results, and 0.1 to 0.87 for medications. Conclusions: Despite differences in data, certain studies may be well-suited for FHIR-based extracts.


  • A REDCap advanced randomization module to meet the needs of modern trials

    by Luke Stevens, Nan Kennedy, Rob J. Taylor, Adam Lewis, Frank E. Harrell, Matthew S. Shotwell, Emily S. Serdoz, Gordon R. Bernard, Wesley H. Self, Christopher J. Lindsell, et al.


  • Open Access

    Multi-scale Data Improves Performance of Machine Learning Model for Long COVID Prediction

    by Wei-Qi Wei, Christopher Guardo, Xinmeng Zhang, Srushti Gandireddy, Chao Yan, Vern Kerchberger, Alyson Dickson, Emily Pfaff, Hiral Master, Melissa Basford, et al.

    Long COVID affects a substantial proportion of the over 778 million individuals infected with SARS-CoV-2, yet predictive models remain limited in scope. While existing efforts, such as the National COVID Cohort Collaborative (N3C), have leveraged electronic health record (EHR) data for risk prediction, accumulating evidence points to additional contributions from social, behavioral, and genetic factors. Using a diverse cohort of SARS-CoV-2-infected individuals (n>17,200) from the NIH All of Us Research Program, we investigated whether integrating EHR data with survey-based and genomic information improves model performance. Our multi-scale approach outperformed EHR-only models original AUROC 0.736 (95% CI: 0.730, 0.741), achieving an AUROC of 0.748 (0.741,0.755). Among the top predictors, active-duty service status, self-reported fatigue, and chr19:4719431:G:A_A were among the most informative survey and genetic features. These findings highlight the importance of incorporating multi-scale data to improve risk stratification and inform personalized interventions for long COVID.

  • Open Access

    Insights from the trial innovation network’s initial consultation process

    by Paul A. Harris, Nan Kennedy, Consuelo H. Wilkins, Karen Lane, Gordon R. Bernard, Jonathan D. Casey, Daniel E. Ford, Salina P. Waddy, Ken L. Wiley, Terri L. Edwards, et al.

    Multicenter clinical trials are essential for evaluating interventions but often face significant challenges in study design, site coordination, participant recruitment, and regulatory compliance. To address these issues, the National Institutes of Health’s National Center for Advancing Translational Sciences established the Trial Innovation Network (TIN). The TIN offers a scientific consultation process, providing access to clinical trial and disease experts who provide input and recommendations throughout the trial’s duration, at no cost to investigators. This approach aims to improve trial design, accelerate implementation, foster interdisciplinary teamwork, and spur innovations that enhance multicenter trial quality and efficiency. The TIN leverages resources of the Clinical and Translational Science Awards (CTSA) program, complementing local capabilities at the investigator’s institution. The Initial Consultation process focuses on the study’s scientific premise, design, site development, recruitment and retention strategies, funding feasibility, and other support areas. As of 6/1/2024, the TIN has provided 431 Initial Consultations to increase efficiency and accelerate trial implementation by delivering customized support and tailored recommendations. Across a range of clinical trials, the TIN has developed standardized, streamlined, and adaptable processes. We describe these processes, provide operational metrics, and include a set of lessons learned for consideration by other trial support and innovation networks.